Pharmaceutical Executive Warren Whitehead Joins Amorfix as Chief Financial Officer

Pharmaceutical Executive Warren Whitehead Joins Amorfix as Chief Financial 
TORONTO, Jan. 31, 2013 /CNW/ - Amorfix Life Sciences Ltd. announced today that 
Mr. Warren Whitehead has joined the Company as Chief Financial Officer 
effective February 1, 2013. Janet Clennett will continue on as part of the 
management team and will assume the position of Director of Finance. 
Mr. Whitehead has been in the pharmaceutical industry for more than 25 years 
and has previously held top management positions in a number of leading 
private and publicly owned pharmaceutical companies. Prior to joining 
Amorfix, Mr. Whitehead was CFO at Arius Research Inc., where he provided 
financial guidance and leadership during the acquisition of ARIUS by Roche in 
2008 and prior to that he was CFO at Labopharm, Inc. where he completed a 
series of public equity financings and a NASDAQ IPO. He is currently a member 
of the Board of Directors of PlantForm Corporation and of Lorus Therapeutics. 
"We are pleased to have such an experienced financial executive join the 
senior management at Amorfix", said Dr. Robert Gundel, Amorfix President and 
Chief Executive Officer. "Mr. Whitehead's financial expertise and his vast 
experience in both the biotechnology industry and the financial sector will 
provide the necessary leadership to advance our products through to 
commercialization, while maximizing returns to our shareholders". 
Dr. Neil Cashman, Amorfix founder and Chairman of the Board said, "On behalf 
of the Board of Directors, I would like to thank Janet Clennett for all of her 
hard work and dedication to Amorfix over the past few years and we are pleased 
that Ms. Clennett will remain as a valuable member of the Amorfix management 
team in her new role. We welcome Mr. Whitehead to the Company and look 
forward to working with him as part of the management team." 
About Amorfix
Amorfix Life Sciences Ltd. (TSX:AMF) is an early-stage product development 
company developing therapeutic antibodies and diagnostics targeting misfolded 
protein diseases. Amorfix utilizes its computational discovery platform, 
ProMIS™, to predict novel Disease Specific Epitopes (DSEs) on the molecular 
surface of misfolded proteins. Using this technology, Amorfix is developing 
novel antibody therapeutics and companion diagnostics for cancer and 
amyotrophic lateral sclerosis (ALS). In addition, Amorfix has developed two 
proprietary technologies to specifically identify very low levels of misfolded 
proteins in a biological sample: Epitope Protection™ and AMFIA™, an 
ultra-sensitive dual-bead immunoassay. Use of these technologies has 
generated a cerebrospinal fluid (CSF) screening test for both Alzheimer's 
disease (AD) and mild cognitive impairment (MCI), and an ultrasensitive method 
for detecting the hallmark of AD, aggregated beta-Amyloid, in brain tissue, 
CSF and blood from animal models of AD. For more information about Amorfix, 
The TSX has not reviewed and does not accept responsibility for the adequacy 
or accuracy of this release. This information release may contain certain 
forward-looking information. Such information involves known and unknown 
risks, uncertainties and other factors that may cause actual results, 
performance or achievements to be materially different from those implied by 
statements herein, and therefore these statements should not be read as 
guarantees of future performance or results. All forward-looking statements 
are based on the Company's current beliefs as well as assumptions made by and 
information currently available to it as well as other factors. Readers are 
cautioned not to place undue reliance on these forward-looking statements, 
which speak only as of the date of this press release. Due to risks and 
uncertainties, including the risks and uncertainties identified by the Company 
in its public securities filings, actual events may differ materially from 
current expectations. The Company disclaims any intention or obligation to 
update or revise any forward-looking statements, whether as a result of new 
information, future events or otherwise, unless required by law. 
ProMIS™, Epitope Protection™ and AMFIA™ are trademarks of Amorfix Life 
Sciences Ltd. 
Dr. Robert Gundel President and Chief Executive Officer Amorfix Life Sciences 
Ltd. Tel: (416) 847-6957 Fax: (416) 847-6899 
SOURCE: Amorfix Life Sciences Ltd. 
To view this news release in HTML formatting, please use the following URL: 
CO: Amorfix Life Sciences Ltd.
ST: Ontario
NI: MTC 2575 WNEWS  
Press spacebar to pause and continue. Press esc to stop.